KEAP1 and ovarian cancer: By analysing the data, Xia et al. demonstrated that cisplatin resistance in human ovarian cancer cells was attributed to the regulation of the Keap1-Nrf2-ARE signalling pathway by ovarian cancer cells through the high expression of p62 [67].